IceCure Medical Ltd.
ICCM Healthcare Medical Devices
IceCure Medical Ltd.’s revenue for fiscal 2025 (year ended December 2025) was $3.4 million, up 2.67% from fiscal 2024. In the quarter to June 2026, revenue was flat, EPS fell 2,068.2%, free cash flow grew 3.88% and total debt fell 64.4%, each against the same quarter a year earlier. Revenue growth for three consecutive years.
Follow ICCM
IceCure Medical Ltd. (ICCM) P/E ratio
IceCure Medical Ltd. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 0.0× (October 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
| FY2017 | 0.0× | — |
| FY2016 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Mar 2026 | 0.0× | — |
| Mar 2025 | 0.0× | — |
| Mar 2024 | 0.0× | — |
| Sep 2023 | 0.0× | — |
| 14 more quarters | Free account |
Against its own ten years
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| NXL Nexalin Technology, Inc. compare | n/m |
| INBS Intelligent Bio Solutions Inc. compare | n/m |
| TRIB Trinity Biotech PLC compare | n/m |
| VVOS Vivos Therapeutics, Inc. compare | n/m |
| VNRX VolitionRX Limited compare | n/m |
| ICCM IceCure Medical Ltd. | n/m |
| ADGM Adagio Medical Holdings, Inc. compare | n/m |
| IVF INVO Fertility, Inc compare | 0.0× |
| BJDX Bluejay Diagnostics, Inc. compare | 0.9× |
| Medical Devices industry median | 23.2× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)